<DOC>
	<DOCNO>NCT00090844</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Chemoprotective drug , triptorelin , may protect normal ovarian cell side effect chemotherapy . PURPOSE : This randomized phase II trial study well triptorelin work preserve ovarian function premenopausal woman receive chemotherapy early-stage breast cancer .</brief_summary>
	<brief_title>Triptorelin Preserving Ovarian Function Premenopausal Women Receiving Chemotherapy Early-Stage Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine protective effect chemical ovarian suppression use triptorelin preservation ovarian function premenopausal woman early-stage operable breast cancer undergo adjuvant neoadjuvant systemic chemotherapy . Secondary - Determine rate chemotherapy-related amenorrhea patient treat drug . - Determine value inhibin A B alternative marker premature ovarian failure patient treat drug . - Determine quality life patient treated drug . - Determine disease-free overall survival patient treated drug . OUTLINE : This randomize , multicenter study . Patients stratify accord age ( &lt; 35 year vs 35 39 year vs &gt; 39 year ) ; concurrent neoadjuvant adjuvant systemic chemotherapy ( fluorouracil , epirubicin , cyclophosphamide [ 6 course ] OR fluorouracil , doxorubicin , cyclophosphamide [ 6 course ] vs doxorubicin cyclophosphamide [ AC ] [ 4 course ] vs doxorubicin cyclophosphamide [ AC ] [ 4 course ] follow taxane [ 4 course ] ) ; hormone receptor status ( estrogen receptor [ ER ] - AND progesterone receptor [ PR ] -negative v ER- OR PR-positive ) . - Arm I : Beginning within 1-4 week start chemotherapy , patient receive triptorelin intramuscularly monthly 4-6 month neoadjuvant adjuvant systemic chemotherapy . - Arm II : Patients receive neoadjuvant adjuvant systemic chemotherapy . Quality life assess baseline , monthly treatment , every 6 month 2 year , annually 3 year . Patients follow every 6 month 2 year annually 3 year . PROJECTED ACCRUAL : A total 138 patient ( 69 per treatment arm ) accrue study within 35 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Drug-Related Side Effects Adverse Reactions</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Earlystage , operable disease Scheduled receive adjuvant neoadjuvant systemic chemotherapy breast cancer Hormone receptor status : Meets 1 follow criterion : Estrogen receptor ( ER ) OR progesterone receptor ( PR ) positive ER AND PRnegative No history premature ovarian failure PATIENT CHARACTERISTICS : Age Under 45 Sex Female Menopausal status Premenopausal Folliclestimulating hormone level &lt; 40 IU/L baseline AND least 2 menstrual period within past 6 month No firstdegree relative menopausal &lt; 40 year age Performance status Eastern Cooperative Oncology Group [ ECOG ] 01 Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant nursing Fertile patient must use effective nonhormonal method contraception No prior osteoporosis nonmalignant systemic disease would preclude prolonged followup No known allergy gonadotrophinreleasing hormone agonists No cancer except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No prior chemotherapy Endocrine therapy At least 2 week since prior oral contraceptive No prior fertility treatment Clomiphene pergonal polycystic ovarian disease allow No concurrent oral transdermal hormonal therapy , include follow : Estrogen Progesterone Androgens Aromatase inhibitor Hormone replacement therapy Oral contraceptive Radiotherapy No prior ovarian radiotherapy Surgery No prior bilateral oophorectomy No plan oophorectomy hysterectomy within next 2 year Other At least 1 week since prior warfarin History premature ovarian failure Over 45 year age Firstdegree relative menopausal &lt; 40 year age Pregnant nursing Prior osteoporosis nonmalignant systemic disease would preclude prolonged followup Known allergy gonadotrophinreleasing hormone agonists Other cancer besides nonmelanoma skin cancer Prior chemotherapy Prior ovarian radiotherapy Prior bilateral oophorectomy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>hormone change</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
</DOC>